Overview

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Status:
Recruiting

Trial end date:
2026-11-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of Obinutuzumab in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line glucocorticoid treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Institute of Hematology & Blood Diseases Hospital, China

Treatments:

Obinutuzumab